Education Corner

Respiratory Syncytial Virus (RSV) is a common and highly contagious respiratory virus that can cause illnesses ranging from a mild cold to lower-respiratory-tract infections such as bronchiolitis and pneumonia. Infants and young children, older adults, and people with weakened immune systems face a higher risk of serious complications after infection.
Early symptoms in babies
In the early stage, RSV infection in babies often resembles a common cold and may include:
-
Fever, runny nose, and nasal congestion
-
Cough and throat discomfort
-
Reduced appetite, low energy, or tiredness
-
In some young children, middle-ear infection (otitis media)
If the virus affects the lower airways, a baby may develop rapid breathing, wheezing, breathing difficulty, feeding difficulty, or marked tiredness. In severe cases, it can progress to bronchiolitis or pneumonia; RSV is one of the important causes of bronchiolitis and pneumonia in infants under one year old.
Seek medical care promptly or go to the emergency department if a baby has rapid breathing, chest indentation, blue or purple lips or face, difficulty feeding or drinking milk, unusual sleepiness, or a poor response.
How RSV spreads?
RSV spreads mainly through:
-
Respiratory droplets produced when an infected person coughs or sneezes
-
Direct contact with secretions such as nasal mucus or saliva
-
Touching contaminated toys, cots, tableware, or door handles and then touching the eyes, nose, or mouth
The virus can survive for several hours on hard surfaces such as toys, cots, and tableware. Frequent handwashing and preventing people with respiratory symptoms from kissing or having close contact with babies can help reduce transmission.
Who can be infected?
RSV can infect people of any age, but the risk and severity differ by group.
| Group | Common situation after infection |
| Infants and young children | More likely to develop lower-respiratory-tract infections such as bronchiolitis and pneumonia; severe cases may require hospitalisation |
| Healthy adults | Usually have only mild cold-like symptoms, but can still transmit the virus to babies or older adults |
| Adults aged 60 or above | Infection can cause serious lower-respiratory-tract disease and pneumonia, with a higher risk of hospitalisation |
| People with chronic illnesses or weakened immunity | More susceptible to more severe respiratory infections |
Even if a baby at home has not been infected, adults or older family members can be sources of transmission. While protecting babies, families should not overlook RSV risk among older adults. People at higher risk—particularly those with chronic lung disease, cardiovascular disease, diabetes, chronic kidney disease, or liver disease—should ask a doctor whether vaccination is appropriate.
RSV vaccines: how are they given?
Hong Kong currently has two registered RSV vaccines: AREXVY and ABRYSVO®, both given as a single dose.
-
AREXVY is indicated for all adults aged 60 or above, as well as high-risk adults aged 50 to 59. High-risk groups include people with chronic conditions such as chronic obstructive pulmonary disease (COPD), asthma, cardiovascular disease, diabetes, chronic kidney disease, or liver disease.
-
ABRYSVO® can be given during pregnancy at 32 to 36 weeks of gestation. Antibodies pass through the placenta to the fetus, providing protection against severe RSV lower-respiratory-tract disease during the baby’s first six months.
Because RSV vaccines are not given directly to infants, maternal vaccination is the main way to provide vaccine-derived antibody protection to a baby before birth.
Who should consider vaccination?
| Suitable group | Vaccination recommendation |
| Pregnant women at 32 to 36 weeks of gestation | May receive ABRYSVO® to protect babies from birth to 6 months old against severe RSV lower-respiratory-tract disease |
| Adults aged 60 or above | May receive a single-dose RSV vaccine—AREXVY or ABRYSVO®—to prevent RSV-related lower-respiratory-tract disease |
| Adults aged 75 or above and residents of residential care homes | The Hong Kong Centre for Health Protection committee considers individual vaccination an option after medical assessment and informed consent |
| High-risk adults aged 18 to 59 | Should consult a doctor first and decide based on individual health status and risk |
Every person’s situation differs. Doctors generally assess age, gestational age, chronic illnesses, allergy history, and individual risk before advising on vaccination.
Protection and effectiveness
For pregnant women, RSV vaccination helps babies receive antibody protection after birth. Clinical-trial data show that maternal vaccination reduced the risk of severe RSV-related lower-respiratory-tract disease by about 81.8% within the first 90 days after birth, and by about 69.4% within 180 days.
For adults aged 60 or above, RSV vaccines help prevent RSV-related lower-respiratory-tract disease. For example, real-world research during the 2023–24 season found that ABRYSVO® had approximately 79% effectiveness against RSV-related emergency-department visits and approximately 73% against related hospitalisation among adults aged 60 or above.
Vaccine protection decreases over time; available data suggest protection of roughly 70% to 80% after two years.
Everyday prevention tips
Q: If a baby gets RSV, will it definitely develop pneumonia?
No. Most babies develop only mild cold-like symptoms such as a runny nose, cough, and fever, and can gradually recover with home care. However, some infants—especially premature babies, those under 6 months old, and those with congenital heart or lung disease or weakened immunity—are more likely to develop bronchiolitis or pneumonia. Seek immediate medical care if a baby has rapid breathing, wheezing, chest indentation, feeding difficulty, poor alertness, or blue lips.
Q: After a pregnant woman receives the RSV vaccine, will her baby never get RSV?
No. The main purpose of maternal RSV vaccination is to transfer antibodies through the placenta and reduce the baby’s risk of severe RSV lower-respiratory-tract disease during the first six months after birth; it does not guarantee complete protection from infection. A baby can still be infected and have mild cold-like symptoms, but the risk of severe complications and hospitalisation can be substantially reduced.